AU3243393A - Methods and compositions for reducing multi-drug resistance - Google Patents

Methods and compositions for reducing multi-drug resistance

Info

Publication number
AU3243393A
AU3243393A AU32433/93A AU3243393A AU3243393A AU 3243393 A AU3243393 A AU 3243393A AU 32433/93 A AU32433/93 A AU 32433/93A AU 3243393 A AU3243393 A AU 3243393A AU 3243393 A AU3243393 A AU 3243393A
Authority
AU
Australia
Prior art keywords
approximately
human
fatty acid
acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32433/93A
Other languages
English (en)
Inventor
John S Coon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush Presbyterian St Lukes Medical Center
Original Assignee
Rush Presbyterian St Lukes Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush Presbyterian St Lukes Medical Center filed Critical Rush Presbyterian St Lukes Medical Center
Publication of AU3243393A publication Critical patent/AU3243393A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU32433/93A 1991-12-10 1992-12-09 Methods and compositions for reducing multi-drug resistance Abandoned AU3243393A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80518691A 1991-12-10 1991-12-10
US805186 1991-12-10
US98276692A 1992-12-07 1992-12-07
US982766 1992-12-07

Publications (1)

Publication Number Publication Date
AU3243393A true AU3243393A (en) 1993-07-19

Family

ID=27122756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32433/93A Abandoned AU3243393A (en) 1991-12-10 1992-12-09 Methods and compositions for reducing multi-drug resistance

Country Status (8)

Country Link
EP (1) EP0616493A4 (ja)
JP (1) JPH07502274A (ja)
CN (1) CN1076358A (ja)
AU (1) AU3243393A (ja)
CA (1) CA2125279A1 (ja)
IL (1) IL104063A0 (ja)
MX (1) MX9207150A (ja)
WO (1) WO1993011668A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
CA2130025A1 (en) * 1993-08-25 1995-02-26 Robert B. Peery Method of treating fungal infections
WO1995031981A2 (en) * 1994-05-19 1995-11-30 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
JP2002538224A (ja) * 1999-03-09 2002-11-12 プロタルガ，インコーポレーテッド 脂肪酸−抗癌剤複合体およびこの使用
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4889525A (en) * 1982-08-17 1989-12-26 Adamantech, Inc. Sensitization of hypoxic tumor cells and control of growth thereof
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4978622A (en) * 1986-06-23 1990-12-18 Regents Of The University Of California Cytophaga-derived immunopotentiator
JP2558107B2 (ja) * 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4863968A (en) * 1987-04-09 1989-09-05 Merrell Dow Pharmaceuticals Inc. Methods of treating gout with chalcone derivatives
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair

Also Published As

Publication number Publication date
WO1993011668A1 (en) 1993-06-24
EP0616493A1 (en) 1994-09-28
MX9207150A (es) 1993-12-01
CA2125279A1 (en) 1993-06-24
EP0616493A4 (en) 1994-11-09
CN1076358A (zh) 1993-09-22
JPH07502274A (ja) 1995-03-09
IL104063A0 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
US5776891A (en) Compositions for reducing multidrug resistance
US5541232A (en) Treatment of multidrug resistant diseases
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
DE69636531T2 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
UA82328C2 (uk) Парентеральна композиція на основі гідроксіестеру рапаміцину (варіанти) та спосіб її приготування
JPH09507233A (ja) 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US6248752B1 (en) Azabicyclooctane compositions and methods for enhancing chemotherapy
AU3243393A (en) Methods and compositions for reducing multi-drug resistance
EP0491018A1 (en) Use of taurolidine and/or taurultam for the treatment of tumours
US5635515A (en) Therapeutic agents for the treatment of multiple drug resistance of cancers
DE60111352T2 (de) Podophyllotoxin-zusammensetzungen
WO1994008578A2 (en) Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
EP2254570B1 (en) Combination comprising paclitaxel for treating ovarian cancer
Borchmann et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma
JPH0357081B2 (ja)
EP0355604A2 (en) Anti-cancer activity potentiator
EP0923371B1 (en) Pharmaceutical compositions comprising tyrphostins
JP5916040B2 (ja) メトトレキサートをオロチン酸誘導体として投与することでその副作用と毒性を下げる組成物及び方法
Berry et al. Enantiomeric interaction of flurbiprofen in the rat
EP1221847B1 (en) Methods of enhancing chemotherapy
US20110082193A1 (en) Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
JPS6185320A (ja) 抗腫瘍剤効果増強剤
WO1997024459A1 (en) Method for reducing unwanted cellular adhesions
EP0759753A1 (en) Methods and compositions for reducing multidrug resistance
Malviya et al. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer